Skip to content
Head to head

Stoke Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: STOK · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

STOK -0.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
STOKVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price26.81515.02
Change today-0.45%-1.08%
1-year return-4.0%+22.0%
Market cap$1.75B$130.58B
52-week range22.05 – 40.22412.27 – 568.67
Valuation
P/E (TTM)-7.0933.14
P/E percentile, own 5-yr range23rd99th
P/B4.976.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.1215.32
Net profit (TTM)$-7.85M$3.88B
Revenue (TTM)$28.21M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+5.9%+11.8%
Gross margin--85.5%
Operating margin-913.2%33.1%
Net margin-862.1%30.7%
Free cash flow (TTM)$-215.72M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership123.0%96.8%
Insider activity (12mo)24 buy / 26 sell28 buy / 22 sell
Short interest (% of float)16.5%1.9%
Analyst consensus100% buy (6)95% buy / 5% hold (21)
Analyst price target$48 (+80%)$624 (+21%)
StockVane view
StockVane Quant RatingD (33)C (68)
Company
Employees1706,400
Founded20141989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.